Although phase II studies suggested the efficacy of cilengitide against tumours with a methylated MGMT promoter, no OS benefit was observed in phase III trials (CENTRIC: EORTC 26071‐22072) designed to evaluate the addition of cilengitide to standard therapy in patients with methylated O(6)‐methylguanine‐DNA methyltransferase (MGMT) promoter.41, 42. Here, MGMT is linked to neoplasm.